Dual epigenetic modifiers for cancer therapy
oleh: Edurne San José-Enériz, Obdulia Rabal, Xabier Agirre, Julen Oyarzabal, Felipe Prosper
| Format: | Article |
|---|---|
| Diterbitkan: | Taylor & Francis Group 2017-07-01 |
Deskripsi
Epigenetic drug discovery is an emerging strategy for the treatment of cancer and other pathologies. Here, we discuss our recent discovery of first-in-class dual reversible inhibitors of the histone methyltransferase activity of G9a/EHMT2 and DNA methyltransferases showing in vivo efficacy in human tumors. Current and future investigation lines are presented.